Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Prospective, Open-label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Remimazolam for Intravenous Sedation in Paediatric Patients Undergoing Diagnostic and/or Therapeutic Procedures

NCT04851717 is registered in ClinicalTrials.gov with Acacia Pharma Ltd as lead sponsor.

NCT NCT04851717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04851717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Prospective, Open-label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Remimazolam for Intravenous Sedation in Paediatric Patients Undergoing Diagnostic and/or Therapeutic Procedures
Lead sponsor
Acacia Pharma Ltd
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
November 15, 2021
Completion date
October 31, 2027
Enrollment
100 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric all